Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.61 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilansetron SCHEMBL29883543 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL15950 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL7427797 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL29019018 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL29883205 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL7433386 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL5764110 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL3157229 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL3452925 | 0.98 | CYP3A4 (0.59) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL21043399 | 0.88 | CYP3A4 (0.47) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230921-A1 | Combination treatment for depression | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| EP-0601345-B1 | Medicament containing an imidazol-1-yl compound | KALI CHEMIE PHARMA GMBH (DE) | 1996-10-02 | — | — | EP | claimed |
| EP-0601345-A1 | Medicament containing an imidazol-1-yl compound | Kali-Chemie Pharma GmbH (DE) | 1994-06-15 | — | — | EP | claimed |
| WO-2019180176-A1 | COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA AND/OR PSYCHOSIS | SPHERIUM BIOMED, S.L. (ES) | 2019-09-26 | — | — | WO | disclosed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| EP-0895782-A2 | Pharmaceutical compositions of Cilansetron stabilized against racemisation | Solvay Pharmaceuticals GmbH (DE) | 1999-02-10 | — | — | EP | disclosed |
| EP-0601345-B1 | Medicament containing an imidazol-1-yl compound | KALI CHEMIE PHARMA GMBH (DE) | 1996-10-02 | — | — | EP | disclosed |
| US-5438068-A | Treatment of irritable bowel syndrome | KALI-CHEMIE PHARMA (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0601345-A1 | Medicament containing an imidazol-1-yl compound | Kali-Chemie Pharma GmbH (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0297651-B1 | Anellated indole derivatives | DUPHAR INT RES (NL) | 1993-11-03 | — | — | EP | disclosed |
| US-4939136-A | New anellated indole derivatives | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1990-07-03 | — | — | US | disclosed |
| EP-0297651-A1 | Anellated indole derivatives | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR3B 323/4885HTR3A 353/4885CYP3A4 4765/4885 |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | HTR3B 5/4885HTR3A 1/4885CYP3A4 324/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR3B 764/4885HTR3A 1276/4885CYP3A4 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.